Inactive Instrument

Highlights TURG POIN

Equities

TPTX

US90041T1088

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Bristol-Myers Squibb Completes Acquisition of Turning Point Therapeutics	22-08-17	MT
Bristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Deal to Close Wednesday	22-08-16	MT
Bristol-Myers Squibb Company completed the acquisition of Turning Point Therapeutics, Inc. from a group of shareholders..	22-08-14	CI
Biotech stocks pin bounce back hopes on M&A boost	22-08-12	RE
Turning Point Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Turning Point Therapeutics, Inc. Provides Operational and Clinical Update	22-08-08	CI
Bristol Myers Squibb Extends Turning Point Tender Offer	22-07-19	MT
Turning Point Therapeutics to Work With University of Texas MD Anderson Cancer Center on Precision Cancer Therapies	22-06-24	MT
Turning Point Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center to Advance Precision Cancer Therapies	22-06-24	CI
Bristol-Myers Squibb Agrees to Acquire Turning Point Therapeutics for $4.1 Billion	22-06-03	MT
Bristol-Myers Squibb Strikes $4.1 Billion All-Cash Deal to Acquire Turning Point Therapeutics	22-06-03	MT
Turning Point Therapeutics Shares Surge on Bristol Myers Deal	22-06-03	DJ
Bristol Myers to Buy Turning Point Therapeutics for $4.1 Billion	22-06-03	DJ
Bristol-Myers Squibb Agrees to Acquire Turning Point Therapeutics for $4.1 Billion	22-06-03	MT
Bristol Myers boosts cancer drug portfolio with $4.1 bln Turning Point deal	22-06-03	RE
Bristol-Myers Squibb Company entered into a definitive merger agreement to acquire Turning Point Therapeutics, Inc. from a group of shareholders for $3.8 billion.	22-06-02	CI
Earnings Flash (TPTX) TURNING POINT THERAPEUTICS Posts Q1 Revenue $429,000	22-05-10	MT
Turning Point Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Turning Point Says FDA Grants Breakthrough Designation to Drug Candidate Repotrectinib for Lung Cancer	22-05-10	MT
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy	22-05-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights TURG POIN

Equities

TPTX

US90041T1088

Highlights

Filters